DiaGenic has named Paul de Potocki as president and CEO, effective in September.
De Potocki will succeed Henrik Lund, who had been DiaGenic's interim CEO since April. He most recently served as CEO of Aerocrine. He has also served as senior vice president of commercial and strategic development at Biovitrium; and executive vice president of strategic marketing at Fresenius Kabi.
Oslo-based DiaGenic has developed technology to identify gene expression signatures in peripheral blood and the company is focused on developing biomarkers in the field of Alzheimer’s and Parkinson’s diseases. DiaGenic’s Alzheimer’s disease development program includes the CE-marked diagnostic test ADtect for detection of mild to moderate Alzheimer’s disease, and MCItect, which is under development for identifying patients with very early stages of Alzheimer’s disease.